AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 92 min read$BCDA

Altman Peter purchased $4K of BCDA

Altman Peter (President and CEO) purchased 5,000 shares of BioCardia, Inc. (BCDA) at $0.85 on 2026-06-09.

Original reporting
SEC EDGAR · Altman Peter
Published Jun 9, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 10:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCDA
Bullish
medium confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDABullishLow
01

Why it matters

The only new information is the disclosed open-market purchase details (5,000 shares at $0.85, total $4,250) and post-transaction holdings (298,266 shares). No operational or financial guidance is provided.

02

Market read

Traders may note insider buying as a sentiment input, but the transaction size and lack of fundamental updates make it unlikely to drive a sustained repricing.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still does not disclose intent, timing constraints, or whether the purchase is part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: filed 2026-06-09 (same day as transaction)

Background

This is an SEC Form 4 insider transaction for BioCardia, Inc. (BCDA) by its President and CEO, Altman Peter.

Company-level read

Ticker impact

$BCDABullishMedium confidence
Context

BioCardia CEO Altman Peter filed a Form 4 open-market purchase of 5,000 shares at $0.85 on 2026-06-09.

Expected impact

Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider purchases can be read as confidence, but the disclosed size ($4,250) is modest and the filing provides no new operating, financial, or regulatory information.

Market effects

Sector

No clear sector read-through from a small insider open-market purchase.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider purchases can be routine (e.g., compensation-related liquidity needs) and do not necessarily reflect a change in business outlook.

Key entities

  • issuer
    BioCardia, Inc.

    Company whose Form 4 insider transaction was filed (BCDA).

  • insider
    Altman Peter

    President and CEO who purchased 5,000 shares open-market on 2026-06-09.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCDA insider trading history →

Related articles

OCT 19
$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.

rttnews.com2 min
OCT 19
$BCDAHighAI 8/10

BioCardia: FDA Accepts De Novo Pre-Submission for Helix Catheter; Substantive Review, Meeting Expected This Quarter

BioCardia's FDA pre-submission for Helix catheter was accepted, with substantive review and a meeting expected this quarter. The FDA raised no concerns about safety or performance. The company has clinical data from 15 trials supporting potential clearance, which could expand partnerships. According to the company, marketing clearance could enhance opportunities with cardiac biologics developers.

tradingview.com1 min
OCT 19
$BCDAMedAI 8/10

FDA accepts BioCardia pre-submission for Helix catheter

BioCardia Inc. (BCDA) announced the FDA accepted its pre-submission for the Helix catheter, a device for heart agent delivery. The FDA indicated two pathways for clearance and raised no safety concerns. BioCardia expects substantive review and feedback this quarter. The Helix catheter is supported by clinical data from 15 trials with nearly 500 patients.

investing.com2 min
OCT 19
$BCDAHighAI 8/10

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for HelixTM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix TM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter October 19, 2026, Sunnyvale, Calif. BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular an

SEC EDGAR 8-K2 min